Pain management · 2026
Efficacy of glossopharyngeal nerve block in managing pain in head and neck cancer: a retrospective cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sirohiya Prashant, Maurya Prateek, Varshney Himanshu, Gupta Nishkarsh, Ratre Brajesh Kumar, Kumar Balbir, Vig Saurabh, Pandit Anuja, Bhopale Shweta, Gupta Raghav, Mishra Seema
Аннотация
BACKGROUND: Head and Neck Cancer (HNC) causes severe pain from tumor invasion, nerve involvement, and treatment effects. Conventional analgesia, including opioids, may be inadequate or poorly tolerated. Glossopharyngeal nerve block (GNB) offers targeted relief, though evidence in cancer pain is limited.
METHODS: This retrospective cohort study evaluated efficacy and safety of GNB in HNC patients. Eighty-two patients with refractory pain received GNB using 2.2 mL of 40 mg triamcinolone 5 mg bupivacaine via peristyloid or pharyngeal wall approach under ultrasound guidance. Pain was assessed using the Numeric Rating Scale (NRS) at baseline, 15 minutes, 1 day, 1 week, 1 month, and 3 months post-procedure. Opioid use (morphine-equivalent daily dose, MEDD), duration of relief, and complications were recorded.
RESULTS: Baseline NRS score of 8.76 ± 0.88 decreased to 0.98 ± 1.05 at 15 minutes and remained low at 3 months (3.17 ± 1.89; p < 0.0001). At 15 minutes, 98.8% achieved ≥50% pain relief; 81.7% maintained it at 3 months. MEDD dropped from 86.95 mg to 31.87 mg/day (p < 0.0001). Fourteen patients required repeat blocks. Three patients experienced minor transient adverse events.
CONCLUSION: Ultrasound-guided GNB offers rapid, sustained pain relief and reduces opioid use in HNC, showing a favorable safety profile.
METHODS: This retrospective cohort study evaluated efficacy and safety of GNB in HNC patients. Eighty-two patients with refractory pain received GNB using 2.2 mL of 40 mg triamcinolone 5 mg bupivacaine via peristyloid or pharyngeal wall approach under ultrasound guidance. Pain was assessed using the Numeric Rating Scale (NRS) at baseline, 15 minutes, 1 day, 1 week, 1 month, and 3 months post-procedure. Opioid use (morphine-equivalent daily dose, MEDD), duration of relief, and complications were recorded.
RESULTS: Baseline NRS score of 8.76 ± 0.88 decreased to 0.98 ± 1.05 at 15 minutes and remained low at 3 months (3.17 ± 1.89; p < 0.0001). At 15 minutes, 98.8% achieved ≥50% pain relief; 81.7% maintained it at 3 months. MEDD dropped from 86.95 mg to 31.87 mg/day (p < 0.0001). Fourteen patients required repeat blocks. Three patients experienced minor transient adverse events.
CONCLUSION: Ultrasound-guided GNB offers rapid, sustained pain relief and reduces opioid use in HNC, showing a favorable safety profile.